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Glass ionomer cements functionalised with a concentrated paste of chlorhexidine 
hexametaphosphate provides dose-dependent chlorhexidine release over at least 14 months 
Abstract 
Objectives 
The aim of this study was to create prototype glass ionomer cements (GICs) incorporating a 
concentrated paste of chlorhexidine-hexametaphosphate (CHX-HMP), and to investigate the long-
term release of soluble chlorhexidine and the mechanical properties of the cements. The purpose is 
the design of a glass ionomer with sustained anticaries efficacy.  
Methods 
CHX-HMP paste was prepared by mixing equimolar solutions of chlorhexidine digluconate and sodium 
hexametaphosphate, adjusting ionic strength, decanting and centrifuging. CHX-HMP paste was 
incorporated into a commercial GIC in substitution for glass powder at 0.00, 0.17, 0.34, 0.85 and 1.70% 
by mass CHX-HMP. Soluble chlorhexidine release into artificial saliva was observed over 436 days using 
absorbance at 255 nm. Diametral tensile and compressive strength were measured after 7 days’ 
setting (37°C, 100% humidity) and tensile strength after 436 days’ aging in artificial saliva. 0.34% CHX-
HMP GICs were tested for their ability to inhibit growth of Streptococcus mutans in vitro.  
Results 
GICs supplemented with CHX-HMP exhibited a sustained dose-dependent release of soluble 
chlorhexidine. Diametral tensile strength of new specimens was unaffected up to and including 0.85% 
CHX-HMP, and individual values of tensile strength were unaffected by aging, but the proportion of 
CHX-HMP required to adversely affect tensile strength was lower after aging, at 0.34%. Compressive 
strength was adversely affected by CHX-HMP at substitutions of 0.85% CHX-HMP and above.  
Conclusions 
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Supplementing a GIC with CHX-HMP paste resulted in a cement which released soluble chlorhexidine 
for over 14 months in a dose dependent manner. 0.17% and 0.34% CHX-HMP did not adversely affect 
strength at baseline, and 0.17% CHX-HMP did not affect strength after aging. 0.34%  CHX-HMP GICs 
inhibited growth of S. mutans at a mean distance of 2.34 mm from the specimen, whereas control 
(0%) GICs did not inhibit bacterial growth.  
 
Clinical Significance 
Although GICs release fluoride in vivo, there is inconclusive evidence regarding any clinical anticaries 
effect. In this study, GICs supplemented with a paste of chlorhexidine-hexametaphosphate (CHX-HMP) 
exhibited a sustained release of chlorhexidine over at least 14 months, and small additions of CHX-
HMP did not adversely affect strength.  
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Introduction  
Glass ionomer cements (GICs) are used for a number of purposes, including as direct restorative 
materials, lining and luting materials, adhesives, and in atraumatic restorative therapy. GIC 
restorations typically have shorter lifetimes than composites or amalgams (1-3), although the reasons 
for this are complex and, of course, the materials are not selected at random but are chosen by the 
clinician according to clinical need. When a GIC does fail, there are a number of potential reasons, one 
of which is secondary caries; this is responsible for 25% of failures of GIC-lined restorations after 18 
years of clinical service (4) and around 18% of GIC failures over a range of 0.1-23 years (5).  
GICs leach fluoride into the oral environment. This results in elevated fluoride concentrations close to 
the restoration, and thus there is an hypothesis that this may reduce dental caries in the local area 
owing to the interaction of the fluoride ion with the hydroxyapatite in the enamel and dentine. This 
hypothesis is broadly supported by in vitro data, but in situ and clinical studies of caries incidence in 
the vicinity of fluoride-releasing restoratives do not show consistent results (6). At the current time it 
is not possible to conclude whether fluoride release from GICs provides lasting protection against 
dental caries (6, 7).  
Chlorhexidine (CHX) is a biocide with broad spectrum efficacy against a wide range of microbes. Its 
main application in dentistry is as a topical agent, usually in oral care products, products for treatment 
of periodontal disease, and varnishes. CHX is efficacious against the microbes implicated in dental 
caries, and is used in a number of products designed to protect the dentition against decay. However, 
the CHX salts in currently available commercial form have poor retention in situ, providing typically a 
few hours of antimicrobial function. One commercial material used for treatment of periodontal 
disease provides some sustained CHX release, but this is a short-term effect with 80% of the CHX 
released within the first 2 days, and a very slow release over the following 3-4 weeks (8).  
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There have been a number of attempts to incorporate CHX into GICs, with the aim of creating a 
restorative material that offers lasting protection against caries. GICs doped with CHX diacetate and 
CHX digluconate have been reported, and these inhibited growth of Streptococcus mutans and 
Lactobacillus acidophilus, but there was also some deterioration of mechanical properties and the 
antimicrobial effects were limited to the first 40-90 days of the study, with no bactericidal effect 
observed after this time (9). There are also reports of an increase in porosity and setting time and a 
reduction in hardness and tensile bond strength when GICs are doped with CHX digluconate (10, 11). 
CHX diacetate and CHX hydrochloride have also been incorporated into GICs, and these too inhibited 
growth of caries-causing organisms, but CHX release was only observed for 24 h so it is not clear how 
long this effect would be sustained (12). CHX diacetate doped resin modified GICs exhibited some 
sustained release of CHX, although this reached completion in 14-21 days (13). The release profiles of 
soluble CHX from GICs doped with these conventional salts of CHX exhibit a high initial release 
followed by little or no sustained release, and this perhaps explains the cytotoxic effects observed 
against fibroblasts when GICs were doped with 1 % CHX diacetate (14). However, supplementation of 
a resin-modified GIC with CHX digluconate at modest concentrations (1.25%) had no adverse effects 
on osteoblasts in vitro and resulted in an elimination of Streptococcus mutans populations following 
indirect pulp treatment in vivo (15), suggesting a potential clinical benefit of a CHX-functionalised 
restorative material.  
We have previously reported the use of a novel salt of CHX: CHX-hexametaphosphate (CHX-HMP) (16). 
CHX-HMP has a lower solubility than CHX digluconate or CHX diacetate and, when used as a coating 
or dopant, can confer a sustained release of CHX that persists for at least three months (17). We have 
described the use of CHX-HMP as a filler for GICs (18). In that study, large clusters of CHX-HMP particles 
were used, and the size of these large particles, which were formed due to the production process, is 
likely to account for the adverse effects on the mechanical properties observed. The aim of the study 
described here was to investigate the use of CHX-HMP particles as GIC fillers but using a new 
preparation method which omits the drying process which creates the large aggregates and instead 
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uses a process of ionic strength adjustment and centrifugation to sequester the particles. CHX release 
was probed over a clinically relevant timescale of over one year, and both compressive and tensile 
strength were investigated; the latter was measured also after 14 months’ aging to determine if the 
modification of the cement adversely affects long-term mechanical properties.  
The hypothesis was that the prototype cements incorporating a concentrated paste of CHX-HMP 
particles would confer a more sustained CHX release, sufficient to inhibit growth of cariogenic 
microbes, coupled with less adverse effects on mechanical properties in comparison to large, dry 
aggregates of CHX-HMP or conventional salts of CHX such as digluconate or diacetate.  
Methods 
Preparation of CHX-HMP paste 
Aqueous 10 mM solutions of CHX digluconate and sodium HMP were prepared. 100 mL of each 
solution were combined in a glass beaker under ambient laboratory conditions. The suspension 
created was stirred vigorously for approximately 1 min, then 30 mL 1 M potassium chloride was added. 
Stirring continued for a further 1 min before the preparation was allowed to settle for 24 h. The 
precipitate settled at the bottom of the flask and the supernatant was gently discarded leaving a 
concentrated suspension of the precipitate. This suspension was then centrifuged at 4760 g for 30 
min. The supernatant was again discarded and the pellet of paste was removed from the centrifuge 
tubes using a spatula and used immediately.  
Preparation of specimens  
A commercially available GIC, Diamond Carve™ (Kemdent Ltd, Purton, UK), was used as the base 
material to create the experimental cements. This GIC comprises a powder, consisting of alumina-
silica based glass filler particles which contain calcium fluoride and other minor salt components and 
freeze dried poly(vinyl)phosphonic acid, and a liquid, which contains polyacrylic and tartaric acids. The 
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manufacturers’ instructions indicate that the powder and liquid should be mixed in a 4:1 ratio by mass 
to create the finished cement.  
The water content of the paste was established to allow the concentration of the liquid component of 
the GIC to be adjusted to account for the additional water in the CHX-HMP paste. CHX-HMP paste was 
weighed as freshly prepared, then stored at 37oC and weighed periodically until the mass of the 
powder was constant, indicating that the available water had evaporated (24 h). This revealed a 
composition of 83% water and 17% CHX-HMP particles. The GIC liquid component was thus prepared 
at a concentration that resulted in the standard final concentration when diluted by the paste. The 
paste was substituted for the overall mass at 0, 0.17, 0.34, 0.85 and 1.70 % by mass of CHX-HMP (0, 
1, 2, 5 and 10% by mass of the paste). The paste was mixed into the liquid first and then the powder 
was added to the paste-liquid combination. Mixing of the specimens was completed in 40-50 s and 
packing into the moulds took a further 10 s, such that all manipulation of the cement was completed 
within 1 min.  
GICs were packed, using a stainless steel spatula, into stainless steel moulds with dimensions of 6 mm 
height and 4 mm diameter (for compressive strength determination) or 4 mm height and 6 mm 
diameter (for measurement of diametral tensile strength and elution of CHX). The moulds were lined 
with a thin layer of petroleum jelly to aid removal of the set cement. Immediately after packing, the 
moulds were placed between two sheets of acetate and a 2 kg weight placed on top of the specimens 
on a flat surface in order to ensure even distribution of the cement. After 5 minutes the specimens 
were sanded using a P120 grit sanding disc (Hermes, Hamburg, Germany) to remove excess material 
and were then placed into small, sealed plastic vessels containing wet tissue paper packed into the lid 
to achieve 100% humidity without direct contact with water. Specimens were stored at 37oC for 7 days 
prior to any further testing to ensure the setting process had reached completion.  
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Compressive strength (CS) testing 
CS was measured by applying a compressive force to the flat surface of the cylindrical specimens using 
a universal testing machine (Zwick/Roell Universal Testing Machine, Zwick/Roell, Leominster, 
Herefordshire, UK) and recording the load at fracture. Specimens were examined after fracture for 
evidence of flaws on the internal or external surfaces and data from flawed specimens were rejected. 
Load at fracture LF was used with diameter D to calculate CS according to the relationship CS = 4L/πD2. 
The load was used in conjunction with the average diameter of the specimen. Specimen dimensions 
were measured three times using a digital micrometer. N = 24 specimens per group were used. Data 
were analysed using a one-way ANOVA followed by a Tukey Honestly Significant Difference post-hoc 
test. 
Diametral tensile strength (DTS) testing 
DTS was measured by applying a compressive force to the curved sides of the cylindrical specimen 
using a universal testing machine and recording the load at fracture. Specimens were examined after 
fracture for evidence of flaws on the internal or external surfaces and data from specimens found to 
be flawed were rejected. The load at fracture LF was used in conjunction with the average diameter D 
and height h of the specimens to calculate DTS according to the relationship DTS = 2L/πDh. Specimen 
dimensions were measured three times using a digital micrometer.  
N = 24 specimens per group were used for the “new” specimens; these were prepared, allowed to set 
for 7 days then tested immediately. Specimens were also tested after 436 days’ elution, to establish 
the diametral tensile strength of “aged” specimens. N = 15 specimens were used for this test. Data 
were analysed using one-way ANOVA followed by Tukey Honestly Significant Difference post-hoc 
tests. 
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Characterisation of CHX release 
GIC specimens were weighed using a precision balance then placed in individual cuvettes (Z637157-
100EA, Sigma-Aldrich, Gillingham, UK) transparent to ultraviolet (UV) light. 1.5 mL artificial saliva was 
added to each cuvette. The artificial saliva was composed of 0.9 mM CaCl2, 0.2 mM MgCl2, 4.0 mM 
KH2PO4, 30.0 mM KCl, 20.0 mM HEPES buffer, titrated to pH of 6.8. The cuvettes were sealed with 
tightly-fitting lids (SEMA2533, VWR, Lutterworth, UK) and then placed onto an orbital shaker (SSM1, 
Stuart, Staffordshire, UK) at 150 rpm and readings taken initially once a day, and less frequently as 
CHX release decelerated. Artificial saliva was refreshed at two-week intervals to avoid any decrease in 
CHX release that could be attributed to saturation of the artificial saliva with respect to CHX salts. 
Adsorption of light at wavelength 255 nm was measured at regular intervals using a 
spectrophotometer (Hitachi U-1900, Hitachi, Japan) and calibration standards of 5 – 50 µM CHX used 
as references to establish CHX release from the GICs into the artificial saliva (19). This was converted 
to μmoles CHX released per unit surface area for each specimen and normalised by subtracting the 
mean reading for the 0% substitution, correcting for other eluents of the GIC such as the polyacrylic 
acid (18). N = 15 specimens per group were used. 
Microbiological testing 
Streptococcus mutans GS-5 was cultivated anaerobically at 37 oC on BHYN agar (per litre: 37 g Brain 
Heart Infusion, 5 g yeast extract, 5 g Neopeptone, 15 g agar). Suspension cultures were grown in BHY 
medium (per litre: 37 g Brain Heart Infusion, 5 g yeast extract) in sealed bottles and incubated 
stationary at 37 oC for 16 h. Bacterial cells were washed once with phosphate-buffered saline (PBS) by 
alternate centrifugation (5000 g, 7 min) and suspension, and suspended in PBS at OD600 1.0 
(approximately 2 x 108 cells/ml). A lawn of bacterial growth was generated by spreading 100 l of 
adjusted S. mutans suspension onto a BHYN agar plate, which was then incubated anaerobically at 37 
oC for 16 h. 
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The GIC specimens were made using the method described above in a 0% (control) and a 0.34% 
substitution. These specimens were prepared using a sterile spatula and moulds in a biological safety 
cabinet (ESCO airstream, ESCO micro pte ltd, Singapore). The specimens were left to mature in a moist 
environment for 7 days at 37 oC, then placed onto the bacterial lawn plates (with minimal force to 
ensure no movement once in the incubator). Lawn plates were incubated for 16 h at 37 oC under 
anaerobic conditions and the zones of inhibition (clearance) measured by diameter.  
Results 
Compressive strength 
Rejection of specimens with internal voids, imperfections or non-linear force-distance curves resulted 
in final n per specimen group of 16-21 (mean n = 19). CS data are shown in Figure 1. There was no 
statistically significant difference between CS of control, 0.17 or 0.34% CHX-HMP specimens. 0.85 CHX-
HMP had significantly lower CS than control, 0.17 or 0.34% specimens, and 1.70% CHX-HMP had 
statistically significantly lower CS than all other groups.  
Diametral tensile strength 
Rejection of specimens with internal voids, imperfections or non-linear force-distance curves resulted 
in final n per specimen group of 18-24 (mean n = 21). DTS data are shown in Figure 2. The only group 
that was statistically significantly different from the control was the 1.70 % CHX-HMP, which had a 
reduced DTS (p<0.0001). 0.17 and 0.34% CHX-HMP had a numerically higher DTS than control 
specimens but this was not statistically significant (p=0.981 and 0.638 respectively). 
Diametral tensile strength of aged specimens 
Rejection of specimens with internal voids, imperfections or non-linear force-distance curves resulted 
in final n per specimen group of 10-13 (mean n = 11.6) for specimens aged for 436 days. DTS data are 
shown in Figure 3. It can be seen that there were numerical changes in DTS compared to baseline 
10 
 
values, but these were not statistically significant. For the aged specimens, 0% and 0.17% formed a 
homogeneous group, 0.34% was significantly lower than 0 and 0.17%, and 0.85% and 1.70% were 
significantly lower still.  
Characterisation of CHX release 
Elution of soluble CHX from CHX-HMP doped GICs normalised to control specimens are shown in 
Figure 4 and Figure 5. Figure 4 shows mean cumulative CHX elution for specimens with 1.70% CHX-
HMP at all time points measured. The purpose of displaying the data in this way is to illustrate the 
smooth curve, indicating that the practice of refreshing the artificial saliva elution medium at 14 day 
intervals was sufficient to prevent saturation with respect to CHX salts from inhibiting the release of 
further CHX. There is a slight suggestion that there is a step in CHX concentration between day 28 and 
day 29 (ie before and after a saliva change) but no other such step changes or accelerations of CHX 
elution are observed.  
In Figure 5, data from day 14x is shown illustrating CHX release as a function of time and dose of CHX-
HMP. A dose response is observed, with greater CHX-HMP substitution in the GIC resulting in a greater, 
and faster, release of CHX-HMP throughout the experimental period. All specimens groups were still 
releasing CHX at the conclusion of the experiment, with the greatest release observed for the higher 
CHX-HMP substitutions.  
The mean cumulative CHX release at each 14x day time was compared to the lowest substitution, to 
establish the relationship between CHX-HMP dose and CHX release. There was a non-linear 
relationship between CHX-HMP dose and CHX release; while the ratio of CHX-HMP concentration for 
0.17, 0.34, 0.85 and 1.70 % CHX-HMP was 1:2:5:10, the ratio of CHX release was 1:4.6:12.3:30.6.  
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Microbiological testing 
0.34% CHX-HMP GICs exhibited zones of inhibition on the lawn of Streptococcus mutans. The mean 
zone of inhibition was 2.34 mm (standard deviation 1.19 mm) from the periphery of the specimen. 
The control GICs displayed no zones of inhibition. 
Discussion 
CHX-HMP particles in a concentrated aqueous paste were prepared and incorporated into a 
commercial GIC, using a bespoke polyacid formulation to correct for the water fraction of the CHX-
HMP paste. The experimental GICs exhibited a sustained release of aqueous CHX into artificial saliva. 
This CHX release continued for the duration of the experiment (436 days), and although all decelerated 
over the course of the experiment, even the lowest substitution (0.17%) had a gradient >0 at the 
conclusion of the experiment. For the higher substitutions there was still a steady and substantial 
release of CHX when the experiment concluded.  
The CHX release observed from GICs supplemented with CHX-HMP was sustained for much longer 
than that achieved using CHX digluconate or CHX diacetate as the dopant (9). This is likely to be owing 
to the low solubility of CHX-HMP; the CHX salt is added as a solid filler which is incorporated into the 
GIC structure, only releasing its soluble CHX payload as some of the particles gradually dissociate. This 
is in contrast to the approach of supplementing a GIC with CHX digluconate or diacetate; in this case 
the CHX is added either already in solution (digluconate) or as a solid, but highly soluble, filler. It is not 
surprising that these approaches lead to a rapid release of CHX in contrast to CHX-HMP.  
CHX release was dose-dependent, with a non-linear relationship; the greater the CHX-HMP in the GIC, 
the more the CHX release, but CHX release increased faster than CHX-HMP dose. This may reflect a 
less stable structure for the higher substitutions; with the higher dopings of CHX-HMP, the particles 
disrupt the setting process of the GIC, meaning that the GIC is more porous and the CHX-HMP particles 
embedded deep within the cement structure are “accessible” to the artificial saliva and contribute to 
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the CHX release. In contrast, those with lower dopings of CHX-HMP have an effective setting process 
and the particles that contribute to the CHX release are only those close to the GIC’s external surface. 
This is supported by the mechanical property data (discussed below) which indicates that the higher 
dopings of CHX-HMP adversely affect the material’s strength.  
The presence of soluble CHX in the elution medium was insufficient during the experiments to restrict 
any further CHX release owing to the large solution:surface area ratio, the agitation of the reaction 
vessels (cuvettes) and the regular changes of artificial saliva. It should be noted that the conditions 
used in this study are not an accurate representation of the clinical scenario; much higher shear 
conditions and larger volumes of saliva were used in this study than would be in contact with the GIC 
at the margins of a restoration. As such it is likely that the rate of CHX release would be slower in vivo, 
because local low shear forces and small fluid volumes would result in a local saturation with respect 
to CHX. That is to say, it is likely that CHX concentrations at the restoration-tooth interface would be 
higher than reported here, as there is little shear or diffusion to remove the CHX, and that these locally 
high CHX concentrations would likely slow the subsequent release of CHX owing to saturation effects. 
Thus the true duration of CHX release from these cements could only be determined from a study 
with a more accurate depiction of the clinical conditions, but it is hypothesised to be longer than that 
observed here.  
DTS of the GICs was not statistically significantly affected by addition of CHX-HMP, compared to the 
unmodified cement, up to and including 0.85% CHX-HMP (Figure 2). There was a numerical rise in DTS 
up to 0.34% CHX-HMP and then a fall with the lowest value recorded for 1.70% CHX-HMP, but only 
the 1.70% CHX-HMP group differed from the control to a statistically significant degree. DTS of 
specimens aged for 436 days indicated no statistically significant changes compared to the baseline 
values. This is consistent with previously published data, indicating that while flexural strength of GICs 
typically decreases after laboratory aging, by as much as 55% (20), compressive and tensile strengths 
tend to remain similar or increase (21), as was observed here. Although there were increases in DTS 
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for control and 0.17 % CHX-HMP and a decrease in DTS for 0.34% CHX-HMP, these were not 
statistically significant (Figure 3). One outcome of this was that the substitution of CHX-HMP required 
to affect a reduction in DTS was lower with aged specimens; 0.34% CHX-HMP specimens had a 
statistically significantly lower DTS than control specimens after 436 days’ aging, as compared to 
1.70% for new specimens. This development can be attributed to the increase in DTS for control 
specimens, as well as the decrease in DTS for specimens with 0.34% CHX-HMP, associated with aging.  
CS of GICs was affected by addition of CHX-HMP; cements with 0.84 and 1.70% CHX-HMP had 
statistically significantly reduced CS compared with control, but those with 0.17 and 0.34% were 
equivalent to the unmodified cement. CS is acknowledged as one of the more sensitive properties as 
regards modifications to GIC formulations (22) and thus it is not surprising that this parameter was 
affected by CHX-HMP addition more than DTS.  
The lower strengths of the GICs with the higher substitutions of CHX-HMP can be explained by 
observing that, in increasing the doping of CHX-HMP, the ratio of polyacid to glass is altered, with less 
glass to account for the greater proportion of CHX-HMP. This will disrupt the GIC setting process as 
fewer glass particles and thus fewer bi- and trivalent ions are available to cross-link the polyacid 
matrix. Thus those specimens with more CHX-HMP are likely to have a less complete setting reaction, 
and this is likely to explain the reduced strength for these specimens.   
The 0.34% CHX-HMP GIC was tested for its ability to inhibit the growth of oral pathogen Streptococcus 
mutans in vitro. This GIC formulation was selected on the basis that it was the highest substitution of 
CHX-HMP that did not have an adverse effect on initial mechanical properties. It was observed that 
these GICs inhibited growth of the microorganism to a mean distance of 2.34 mm from the periphery 
of the specimen, whereas control GICs displayed no zone of inhibition. This indicates that, in vitro and 
utilising a simple, single species model, the concentration of CHX released by the 0.34% CHX-HMP GIC 
was sufficient to inhibit growth of this cariogenic organism.  
14 
 
The strength data, particularly the DTS of the aged specimens combined with the CS data, suggests 
that if such a GIC were to find clinical application, the lower substitutions of CHX-HMP paste would be 
more suitable, as these have no negative impact on mechanical properties. The 0.34% CHX-HMP GIC, 
which was the highest concentration of CHX-HMP while not adversely affecting mechanical properties 
at baseline, inhibited growth of Streptococcus mutans in an in vitro zone of inhibition model. Noting 
the comments above regarding the experimental conditions, the next step should be to determine 
whether this cement can inhibit the growth of caries-causing microorganisms under flow conditions 
more representative of the clinical environment of a GIC.  
Conclusions 
CHX-HMP particles in a concentrated paste were incorporated into a commercial GIC, with adjustment 
of the acid concentration in the commercial GIC to account for the water in the paste. Higher 
substitutions of CHX-HMP paste (0.85 and 1.70% CHX-HMP by mass, or 5 and 10% paste by mass) had 
a negative impact on compressive strength, but lower substitutions had no significant impact on 
compressive strength. None of the prototype cements displayed a reduction in diametral tensile 
strength at baseline; DTS after 436 days aging was not statistically significantly different when 
comparing specimens with and without aging, although the substitutions of 0.34% and higher were 
significantly weaker than the control cement after aging. All of the prototype cements exhibited a 
sustained release of soluble CHX over the 436 day experimental period. 
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Figures 
 
 
Figure 1. CS of GIC specimens as a function of CHX-HMP substitution. Error bars represent 
standard deviations.  
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Figure 2. DTS of GIC specimens as a function of CHX-HMP substitution. Error bars represent 
standard deviations. 
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Figure 3. Diametral tensile strength of newly prepared GIC specimens (“new”) and specimens 
immersed in artificial saliva, refreshed fortnightly, for 436 days (”aged”). p values refer to 
comparisons of new and aged specimens for a given % substitution of CHX-HMP; although 
numerical differences were observed these were not statistically significant.  
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Figure 4. Cumulative CHX release from GIC specimens containing 1.70% CHX-HMP in 
substitution for the powder component. This figure shows data points from all sampling days, 
indicating the smooth transition between the 14 day periods, and no local saturation existing 
prior to artificial saliva change, with one possible exception where there is a step change from 
day 28 (before saliva change) to day 29 (after saliva change) indicating the possibility of some 
minor inhibition of CHX release at this single time point.  
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Figure 5. Cumulative CHX release from GIC specimens as a function of CHX-HMP substitution 
for the powder component of the cement. Data is presented at 14 day intervals.  
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